Allogene Therapeutics Inc (ALLO) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Allogene Therapeutics Inc   (NASDAQ: ALLO)


Allogene Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Allogene Therapeutics Inc's ROI in the second quarter of 2026?
Allogene Therapeutics Inc recorded a cumulative net loss of $-165 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -39.47%.

Within the Healthcare sector 214 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3197 to 3635.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -15.57 % -25.93 % -23.56 % -21.03 % -18.76 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 518 368 383 408 439
Return On Investment (TTM) -39.47 % -43.5 % -44.7 % -46.14 % -47.7 %
ALLO's Overall Ranking # 3635 # 3197 # 2724 # 3252 # 2973
Seq. Investment Change TTM 4.97 % -6.46 % -7.06 % -7.48 % -7.91 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -165 -174 -191 -212 -237

ALLO Company Profile >> Back to ALLO Roi Comparisons >> See Annual ALLO Return On Investment



Return On Investment ALLO's Ranking
Within: No.
Industry # 23
Sector # 215
Overall # 3635

Return On Investment Statistics
High Average Low
-11.34 %
-36.39 %
-63.09 %
(Sep 30 2019)   (Sep 30 2018)



  News about Allogene Therapeutics Inc Return on Investment ROI

Pioneering the Future Allogene Therapeutics Unveils Promising ALLO-316 Data for Advanced Renal Cancer,

November 7, 2024

Innovative Progress: Allogene Therapeutics Phase 1 Success in Treatment-Resistant Renal Cell Carcinoma In a vibrant stride toward advancing cancer treatment, Allogene Therapeutics, Inc. (NASDAQ: ALLO) has revealed promising Phase 1 data demonstrating the potential of its groundbreaking ALLO-316 therapy for patients grappling with advanced renal cell carcinoma (RCC). The data will be shared with the scientific community through an oral presentation at the 2024 International Kidney Cancer Symposium (IKCS) and a poster session at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting, showcasing Allogene’s pioneering work in the field of allogeneic CAR T cells.Renal cell carcinoma remains a formidable cancer type, particularly in advanced stages where treatment options wane, making new therapeutic avenues crucial. The TRAVERSE trial by Allogene focuses on this critical need by introducing ALLO-316, the company’s inaugural allogeneic CAR T product candidate, which specializes in treating solid tumors.





Financial Statements
Allogene Therapeutics Inc's II. Quarter Investments $ 518 Millions ALLO's Balance sheet
Allogene Therapeutics Inc's II. Quarter Income $ -43 Millions Quarterly ALLO's Income Statement
ALLO's Income by Division See ALLO's Income by Division


ALLO Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 383 513 606 768 990
Y / Y Investment Growth -25.29 % -15.28 % -21.11 % -22.48 % -12.62 %
Net Income in Millions -191 -258 -327 -340 -257
Y / Y Net Income Growth - - - - -
Annual Return On Investment -49.79 % -50.19 % -54.03 % -44.33 % -25.95 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ALLO's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ALLO's Competitors
Subscribers only: Roi for Allogene Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for ALLO's Customers

Other Ratios
ALLO's Roa ALLO's Inventory Turnover Ratio ALLO's Growth Rates ALLO's Dividend Statistics
ALLO's Profitability Ratios ALLO's Asset Turnover Ratio ALLO's Dividend Growth
ALLO's Roe ALLO's Valuation Ratios ALLO's Financial Strength Ratios ALLO's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:35:44+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.